Abstract Body

Presentation:

Tuberculosis (TB) is among the leading cause of morbidity and mortality from an infectious disease, among patients with and without HIV, worldwide. Despite cost-free 6- months anti-TB therapy (ATT), the cure rates for TB have been suboptimal due to inadequate exposure/ adherence to ATT, causing a higher risk of failure, relapse, or acquired drug resistance, particularly in the setting of HIV. Recent research developments demonstrated that highly potent ATT regimens can allow shortening of TB treatment for both drug-sensitive and drug resistant TB in adult, adolescent and paediatric populations. In addition, shortened TB preventive therapy containing highly potent rifamycins and isoniazid is as good as the traditional 6-9 months of isoniazid prophylaxis among at-risk populations. Furthermore, emerging evidence shows that shortened course TB treatment and prevention regimens may reduce the impact of drug-drug interactions with antiretrovirals. This plenary talk will summarize the most recent research evidence on the shorter course TB prevention and treatment, several of which have now informed the WHO guidelines. Further, the talk will provide an updated information on the drug-drug interactions between ATT and antiretrovirals as well as briefly discuss the recent rapid expansion of TB therapeutics pipeline.